[Form 4] U.S. GoldMining Inc. Common stock Insider Trading Activity
Harvard Bioscience, Inc. (NASDAQ: HBIO) filed an 8-K (Item 3.01) reporting that it is not in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires at least three independent directors on the audit committee. The shortfall arose when director Alan Edrick resigned on 10 June 2025, leaving only two audit-committee members.
The company formally notified Nasdaq on 18 June 2025 and will rely on the cure period allowed under Nasdaq Rule 5605(c)(4). HBIO has until the earlier of its next annual shareholder meeting or 10 June 2026 to appoint a new, fully independent director who also meets Exchange Act Rule 10A-3(b)(1). Management states that it intends to fill the vacancy 鈥渁s expeditiously as practicable.鈥� No other financial data or operational changes were disclosed in this filing.
Harvard Bioscience, Inc. (NASDAQ: HBIO) ha presentato un modulo 8-K (voce 3.01) segnalando di non essere conforme alla Regola di quotazione Nasdaq 5605(c)(2)(A), che richiede almeno tre amministratori indipendenti nel comitato di revisione. Questa carenza 猫 emersa dopo che il direttore Alan Edrick si 猫 dimesso il 10 giugno 2025, lasciando solo due membri nel comitato di revisione.
L'azienda ha notificato formalmente Nasdaq il 18 giugno 2025 e far脿 affidamento sul periodo di rimedio consentito dalla Regola Nasdaq 5605(c)(4). HBIO ha tempo fino al primo tra la sua prossima assemblea annuale degli azionisti o il 10 giugno 2026 per nominare un nuovo direttore completamente indipendente che soddisfi anche la Regola Exchange Act 10A-3(b)(1). La direzione dichiara l'intenzione di coprire la vacanza 鈥渘el pi霉 breve tempo possibile鈥�. Non sono stati divulgati altri dati finanziari o cambiamenti operativi in questa comunicazione.
Harvard Bioscience, Inc. (NASDAQ: HBIO) present贸 un formulario 8-K (Art铆culo 3.01) informando que no cumple con la Regla de listado Nasdaq 5605(c)(2)(A), que exige al menos tres directores independientes en el comit茅 de auditor铆a. La falta se produjo cuando el director Alan Edrick renunci贸 el 10 de junio de 2025, quedando solo dos miembros en el comit茅 de auditor铆a.
La empresa notific贸 formalmente a Nasdaq el 18 de junio de 2025 y se acoger谩 al per铆odo de correcci贸n permitido bajo la Regla Nasdaq 5605(c)(4). HBIO tiene hasta el antes de su pr贸xima junta anual de accionistas o el 10 de junio de 2026 para nombrar un nuevo director completamente independiente que tambi茅n cumpla con la Regla Exchange Act 10A-3(b)(1). La direcci贸n indica que tiene la intenci贸n de cubrir la vacante 鈥渓o antes posible鈥�. No se divulgaron otros datos financieros ni cambios operativos en esta presentaci贸n.
Harvard Bioscience, Inc. (NASDAQ: HBIO)電� 8-K 氤搓碃靹�(Item 3.01)毳� 鞝滌稖頃橂┌ 臧愳偓鞙勳洂須岇棎 斓滌唽 靹� 氇呾潣 霃呺 鞚挫偓毳� 鞖旉惮頃橂姅 Nasdaq 靸侅灔 攴滌箼 5605(c)(2)(A)毳� 欷�靾橅晿歆� 鞎婈碃 鞛堨潓鞚� 鞎岆牳鞀惦媹雼�. 鞚� 攵�臁膘潃 鞚挫偓 Alan Edrick臧� 2025雲� 6鞗� 10鞚� 靷瀯頃橂┐靹� 臧愳偓鞙勳洂須� 氅る矂臧� 霊� 氇呺 雮矊 霅� 雿办劀 氚滌儩頄堨姷雼堧嫟.
須岇偓電� 2025雲� 6鞗� 18鞚� Nasdaq鞐� 瓿奠嫕 韱惦炒頄堨溂氅� Nasdaq 攴滌箼 5605(c)(4)鞐� 霐半澕 鞁滌爼 旮瓣皠鞚� 頇滌毄頃� 鞓堨爼鞛呺媹雼�. HBIO電� 雼れ潓 鞐半 欤检＜齑濏殞 霕愲姅 2026雲� 6鞗� 10鞚� 欷� 牍犽ジ 鞁滌澕 雮挫棎 靸堧…瓿� 鞕勳爠頌� 霃呺鞝侅澑 鞚挫偓毳� 鞛勲獏頃挫暭 頃橂┌, 鞚� 鞚挫偓電� Exchange Act 攴滌箼 10A-3(b)(1)霃� 於╈”頃挫暭 頃╇媹雼�. 瓴届榿歆勳潃 臧�電ロ暅 頃� 鞁犾啀頌� 瓿奠劃鞚� 毂勳毟 瓿勴殟鞛勳潉 氚濏様鞀惦媹雼�. 鞚� 氤搓碃靹滌棎電� 雼るジ 鞛 雿办澊韯半倶 鞖挫榿靸侅潣 氤�瓴� 靷暛鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.
Harvard Bioscience, Inc. (NASDAQ : HBIO) a d茅pos茅 un formulaire 8-K (point 3.01) indiquant qu'elle n'est pas en conformit茅 avec la r猫gle de cotation Nasdaq 5605(c)(2)(A), qui exige au moins trois administrateurs ind茅pendants au sein du comit茅 d'audit. Ce manquement est survenu lorsque le directeur Alan Edrick a d茅missionn茅 le 10 juin 2025, ne laissant que deux membres au comit茅 d'audit.
La soci茅t茅 a officiellement inform茅 Nasdaq le 18 juin 2025 et s'appuiera sur la p茅riode de correction autoris茅e par la r猫gle Nasdaq 5605(c)(4). HBIO dispose jusqu'脿 la date la plus proche entre sa prochaine assembl茅e annuelle des actionnaires ou le 10 juin 2026 pour nommer un nouveau directeur enti猫rement ind茅pendant qui respecte 茅galement la r猫gle Exchange Act 10A-3(b)(1). La direction d茅clare son intention de pourvoir le poste vacant 芦 aussi rapidement que possible 禄. Aucune autre donn茅e financi猫re ou changement op茅rationnel n鈥檃 茅t茅 divulgu茅 dans ce d茅p么t.
Harvard Bioscience, Inc. (NASDAQ: HBIO) reichte ein 8-K Formular (Punkt 3.01) ein und berichtete, dass es nicht den Nasdaq-Listing-Regel 5605(c)(2)(A) entspricht, die mindestens drei unabh盲ngige Direktoren im Pr眉fungsausschuss vorschreibt. Das Defizit entstand, als der Direktor Alan Edrick am 10. Juni 2025 zur眉cktrat, wodurch nur noch zwei Mitglieder im Pr眉fungsausschuss verblieben.
Das Unternehmen informierte Nasdaq formell am 18. Juni 2025 und wird sich auf die unter Nasdaq-Regel 5605(c)(4) erlaubte Nachfrist berufen. HBIO hat bis zum fr眉hesten Zeitpunkt seiner n盲chsten j盲hrlichen Hauptversammlung oder dem 10. Juni 2026 Zeit, einen neuen, vollst盲ndig unabh盲ngigen Direktor zu ernennen, der auch die Exchange Act Regel 10A-3(b)(1) erf眉llt. Das Management gibt an, die Vakanz 鈥瀞o schnell wie m枚glich鈥� zu besetzen. Weitere finanzielle Daten oder operative 脛nderungen wurden in dieser Meldung nicht offengelegt.
- Transparent disclosure: HBIO promptly informed Nasdaq and investors, demonstrating adherence to reporting obligations.
- Cure period available: The company has up to one year (or the next annual meeting) to regain compliance, reducing immediate delisting risk.
- Audit-committee shortfall: Only two independent directors remain after a resignation, breaching Nasdaq Rule 5605(c)(2)(A).
- Governance uncertainty: Failure to seat an independent director by June 10 2026 could expose HBIO to delisting proceedings.
Insights
TL;DR: Minor governance gap; cure window limits immediate risk.
Nasdaq鈥檚 audit-committee rule is fundamental to board oversight, but single-director vacancies are routinely cured within the exchange鈥檚 one-year grace period. HBIO promptly disclosed the issue, preserving transparency and eligibility for the cure window. Because the company still meets other listing standards and articulated a plan to recruit an independent director, delisting risk is low unless the search drags past June 2026. Investors should monitor the timing and qualifications of the replacement to gauge governance quality.
TL;DR: Limited immediate share-price impact; watch for timely board appointment.
The filing flags a compliance deficiency, yet it carries no direct financial ramifications and does not affect ongoing operations. Historically, similar notices have had muted market reactions when companies indicate a clear remediation path. That said, extended vacancies can elevate perceived governance risk and, in some cases, hinder institutional ownership mandates. Absent additional negative developments, the disclosure is neutral to the investment thesis, but investors should expect headline sensitivity if the cure deadline becomes at risk.
Harvard Bioscience, Inc. (NASDAQ: HBIO) ha presentato un modulo 8-K (voce 3.01) segnalando di non essere conforme alla Regola di quotazione Nasdaq 5605(c)(2)(A), che richiede almeno tre amministratori indipendenti nel comitato di revisione. Questa carenza 猫 emersa dopo che il direttore Alan Edrick si 猫 dimesso il 10 giugno 2025, lasciando solo due membri nel comitato di revisione.
L'azienda ha notificato formalmente Nasdaq il 18 giugno 2025 e far脿 affidamento sul periodo di rimedio consentito dalla Regola Nasdaq 5605(c)(4). HBIO ha tempo fino al primo tra la sua prossima assemblea annuale degli azionisti o il 10 giugno 2026 per nominare un nuovo direttore completamente indipendente che soddisfi anche la Regola Exchange Act 10A-3(b)(1). La direzione dichiara l'intenzione di coprire la vacanza 鈥渘el pi霉 breve tempo possibile鈥�. Non sono stati divulgati altri dati finanziari o cambiamenti operativi in questa comunicazione.
Harvard Bioscience, Inc. (NASDAQ: HBIO) present贸 un formulario 8-K (Art铆culo 3.01) informando que no cumple con la Regla de listado Nasdaq 5605(c)(2)(A), que exige al menos tres directores independientes en el comit茅 de auditor铆a. La falta se produjo cuando el director Alan Edrick renunci贸 el 10 de junio de 2025, quedando solo dos miembros en el comit茅 de auditor铆a.
La empresa notific贸 formalmente a Nasdaq el 18 de junio de 2025 y se acoger谩 al per铆odo de correcci贸n permitido bajo la Regla Nasdaq 5605(c)(4). HBIO tiene hasta el antes de su pr贸xima junta anual de accionistas o el 10 de junio de 2026 para nombrar un nuevo director completamente independiente que tambi茅n cumpla con la Regla Exchange Act 10A-3(b)(1). La direcci贸n indica que tiene la intenci贸n de cubrir la vacante 鈥渓o antes posible鈥�. No se divulgaron otros datos financieros ni cambios operativos en esta presentaci贸n.
Harvard Bioscience, Inc. (NASDAQ: HBIO)電� 8-K 氤搓碃靹�(Item 3.01)毳� 鞝滌稖頃橂┌ 臧愳偓鞙勳洂須岇棎 斓滌唽 靹� 氇呾潣 霃呺 鞚挫偓毳� 鞖旉惮頃橂姅 Nasdaq 靸侅灔 攴滌箼 5605(c)(2)(A)毳� 欷�靾橅晿歆� 鞎婈碃 鞛堨潓鞚� 鞎岆牳鞀惦媹雼�. 鞚� 攵�臁膘潃 鞚挫偓 Alan Edrick臧� 2025雲� 6鞗� 10鞚� 靷瀯頃橂┐靹� 臧愳偓鞙勳洂須� 氅る矂臧� 霊� 氇呺 雮矊 霅� 雿办劀 氚滌儩頄堨姷雼堧嫟.
須岇偓電� 2025雲� 6鞗� 18鞚� Nasdaq鞐� 瓿奠嫕 韱惦炒頄堨溂氅� Nasdaq 攴滌箼 5605(c)(4)鞐� 霐半澕 鞁滌爼 旮瓣皠鞚� 頇滌毄頃� 鞓堨爼鞛呺媹雼�. HBIO電� 雼れ潓 鞐半 欤检＜齑濏殞 霕愲姅 2026雲� 6鞗� 10鞚� 欷� 牍犽ジ 鞁滌澕 雮挫棎 靸堧…瓿� 鞕勳爠頌� 霃呺鞝侅澑 鞚挫偓毳� 鞛勲獏頃挫暭 頃橂┌, 鞚� 鞚挫偓電� Exchange Act 攴滌箼 10A-3(b)(1)霃� 於╈”頃挫暭 頃╇媹雼�. 瓴届榿歆勳潃 臧�電ロ暅 頃� 鞁犾啀頌� 瓿奠劃鞚� 毂勳毟 瓿勴殟鞛勳潉 氚濏様鞀惦媹雼�. 鞚� 氤搓碃靹滌棎電� 雼るジ 鞛 雿办澊韯半倶 鞖挫榿靸侅潣 氤�瓴� 靷暛鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.
Harvard Bioscience, Inc. (NASDAQ : HBIO) a d茅pos茅 un formulaire 8-K (point 3.01) indiquant qu'elle n'est pas en conformit茅 avec la r猫gle de cotation Nasdaq 5605(c)(2)(A), qui exige au moins trois administrateurs ind茅pendants au sein du comit茅 d'audit. Ce manquement est survenu lorsque le directeur Alan Edrick a d茅missionn茅 le 10 juin 2025, ne laissant que deux membres au comit茅 d'audit.
La soci茅t茅 a officiellement inform茅 Nasdaq le 18 juin 2025 et s'appuiera sur la p茅riode de correction autoris茅e par la r猫gle Nasdaq 5605(c)(4). HBIO dispose jusqu'脿 la date la plus proche entre sa prochaine assembl茅e annuelle des actionnaires ou le 10 juin 2026 pour nommer un nouveau directeur enti猫rement ind茅pendant qui respecte 茅galement la r猫gle Exchange Act 10A-3(b)(1). La direction d茅clare son intention de pourvoir le poste vacant 芦 aussi rapidement que possible 禄. Aucune autre donn茅e financi猫re ou changement op茅rationnel n鈥檃 茅t茅 divulgu茅 dans ce d茅p么t.
Harvard Bioscience, Inc. (NASDAQ: HBIO) reichte ein 8-K Formular (Punkt 3.01) ein und berichtete, dass es nicht den Nasdaq-Listing-Regel 5605(c)(2)(A) entspricht, die mindestens drei unabh盲ngige Direktoren im Pr眉fungsausschuss vorschreibt. Das Defizit entstand, als der Direktor Alan Edrick am 10. Juni 2025 zur眉cktrat, wodurch nur noch zwei Mitglieder im Pr眉fungsausschuss verblieben.
Das Unternehmen informierte Nasdaq formell am 18. Juni 2025 und wird sich auf die unter Nasdaq-Regel 5605(c)(4) erlaubte Nachfrist berufen. HBIO hat bis zum fr眉hesten Zeitpunkt seiner n盲chsten j盲hrlichen Hauptversammlung oder dem 10. Juni 2026 Zeit, einen neuen, vollst盲ndig unabh盲ngigen Direktor zu ernennen, der auch die Exchange Act Regel 10A-3(b)(1) erf眉llt. Das Management gibt an, die Vakanz 鈥瀞o schnell wie m枚glich鈥� zu besetzen. Weitere finanzielle Daten oder operative 脛nderungen wurden in dieser Meldung nicht offengelegt.
FAQ
Why did Harvard Bioscience (HBIO) receive a Nasdaq notice?
What deadline does HBIO have to regain Nasdaq compliance?
Does the notice affect HBIO's current Nasdaq listing?
Who resigned from HBIO's board and audit committee?
What steps is HBIO taking to resolve the issue?
